Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Cost of Revenue: 2016-2024

Historic Cost of Revenue for Amicus Therapeutics (FOLD) over the last 9 years, with Dec 2024 value amounting to $52.9 million.

  • Amicus Therapeutics' Cost of Revenue rose 46.60% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.2 million, marking a year-over-year increase of 23.85%. This contributed to the annual value of $52.9 million for FY2024, which is 41.84% up from last year.
  • According to the latest figures from FY2024, Amicus Therapeutics' Cost of Revenue is $52.9 million, which was up 41.84% from $37.3 million recorded in FY2023.
  • Over the past 5 years, Amicus Therapeutics' Cost of Revenue peaked at $52.9 million during FY2024, and registered a low of $31.0 million during FY2020.
  • For the 3-year period, Amicus Therapeutics' Cost of Revenue averaged around $43.0 million, with its median value being $38.6 million (2022).
  • As far as peak fluctuations go, Amicus Therapeutics' Cost of Revenue dropped by 3.30% in 2023, and later spiked by 41.84% in 2024.
  • Amicus Therapeutics' Cost of Revenue (Yearly) stood at $31.0 million in 2020, then grew by 11.02% to $34.5 million in 2021, then rose by 11.99% to $38.6 million in 2022, then fell by 3.30% to $37.3 million in 2023, then surged by 41.84% to $52.9 million in 2024.